4 results match your criteria: "University Hospital of Brest - La Cavale Blanche[Affiliation]"

Article Synopsis
  • This study investigated the relationship between Body Mass Index (BMI) and health outcomes in critically ill COVID-19 patients, focusing on metabolic risk factors like diabetes and hypertension.
  • Conducted across 21 medical centers, the research included 1,461 patients and found that over 73% required invasive mechanical ventilation (IMV), with a 28-day mortality rate estimated at 36.1%.
  • Results indicated a positive linear relationship between BMI and the need for IMV, while a nonlinear association linked higher BMI (especially in obesity class III) to increased mortality risk.
View Article and Find Full Text PDF

Objective: To assess how stressful conditions in endotracheal intubation could induct emotional excitation in a population of acute care physicians.

Materials And Methods: Two situations were randomly tested: one in standard and easy intubation conditions the other under difficult conditions presumed to induce stress (monitoring alarms, manikin lying on the floor, difficult intubation). Emotional excitation was assessed using several physiological (cardiac patterns, electrodermal activity and eye-tracking) and psycho-cognitive patterns.

View Article and Find Full Text PDF

Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors.

Eur J Gastroenterol Hepatol

February 2016

aDepartment of Hepato-Gastroenterology bDepartment of Internal Medicine, University Hospital of Brest La Cavale Blanche, Brest cHepatology Department, Pontchaillou University Hospital, Rennes dDepartment of Hepatology and Gastroenterology, Laennec Hospital-GHPSO, Creil, France.

Background And Aims: In many countries, current treatment for patients with chronic hepatitis C involves a combination of peginterferon and ribavirin, associated with a protease inhibitor for hepatitis C virus genotype 1. More recent and efficient less toxic antiviral treatments are now available for some patients. Thus, the decision to treat or to wait is challenging.

View Article and Find Full Text PDF

Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control.

View Article and Find Full Text PDF